These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8218100)

  • 21. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
    Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
    Peerlinck K; De Lepeleire I; Goldberg M; Farrell D; Barrett J; Hand E; Panebianco D; Deckmyn H; Vermylen J; Arnout J
    Circulation; 1993 Oct; 88(4 Pt 1):1512-7. PubMed ID: 8403299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito.
    Yoshida S; Sudo T; Niimi M; Tao L; Sun B; Kambayashi J; Watanabe H; Luo E; Matsuoka H
    Blood; 2008 Feb; 111(4):2007-14. PubMed ID: 18056842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibody-induced inhibition of platelet function: effects on hemostasis and vascular graft thrombosis in baboons.
    Torem S; Schneider PA; Hanson SR
    J Vasc Surg; 1988 Jan; 7(1):172-80. PubMed ID: 3336123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins.
    Beviglia L; Poggi A; Rossi C; McLane MA; Calabrese R; Scanziani E; Cook JJ; Niewiarowski S
    Thromb Res; 1993 Aug; 71(4):301-15. PubMed ID: 8236159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo antithrombotic effect of triflavin, an Arg-Gly-Asp containing peptide on platelet plug formation in mesenteric microvessels of mice.
    Sheu JR; Chao SH; Yen MH; Huang TF
    Thromb Haemost; 1994 Oct; 72(4):617-21. PubMed ID: 7878641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
    Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
    Egbertson MS; Chang CT; Duggan ME; Gould RJ; Halczenko W; Hartman GD; Laswell WL; Lynch JJ; Lynch RJ; Manno PD
    J Med Chem; 1994 Aug; 37(16):2537-51. PubMed ID: 8057299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adhesive domains in the collagen III fragment alpha1(III)CB4 that support alpha2beta1- and von Willebrand factor-mediated platelet adhesion under flow conditions.
    Verkleij MW; IJsseldijk MJ; Heijnen-Snyder GJ; Huizinga EG; Morton LF; Knight CG; Sixma JJ; de Groot PG; Barnes MJ
    Thromb Haemost; 1999 Sep; 82(3):1137-44. PubMed ID: 10494778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.
    Hanson SR; Griffin JH; Harker LA; Kelly AB; Esmon CT; Gruber A
    J Clin Invest; 1993 Oct; 92(4):2003-12. PubMed ID: 8408654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
    Lucchessi BR; Rote WE; Driscoll EM; Mu DX
    Br J Pharmacol; 1994 Dec; 113(4):1333-43. PubMed ID: 7889289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
    Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.